METABIOTICS pp 27-31 | Cite as

Contemporary Microecological Strategies of Gut Microbiota Modulation for Human Health Preservation, Restoration and Improvement

  • Boris A. Shenderov
  • Alexander V. Sinitsa
  • Mikhail M. Zakharchenko
  • Christine Lang


For health preservation and reducing the risk of premature ageing and related metabolic diseases, human diet should include various traditional, organic and functional foods as well as therapeutics that support alimentary and other functions of gut microbiota. To create or restore the impaired human biocenoses, various targeted microecological techniques and methods are used (Table 1), with a focus on either prevention or treatment. In the longer term, these approaches can be used in microecological engineering of pregnant and breastfeeding mothers, as well as infants for shaping their targeted microbial ecology. It should be remembered that though the responses of the host-microbiota system to the implementation of different dietary and microecological agents are on the whole predictable, they can vary considerably from individual to individual as far as their focus, efficiency and distinct manifestations are concerned (Shenderov 2014b; Lenoir-Wijnkoop et al. 2007; Shenderov 2011b; Sonnenburg and Backhed 2016). Since 1950s, over 150 different microecological therapeutics have been developed and produced commercially for prevention and treatment of diseases related to the imbalance of symbiotic microbiota. To preserve and restore human microbial ecology, a wide range of microecological therapeutics are used (probiotics, symbiotics, combiotics, prebiotics, synbiotics, virobiotics (including phagobiotics), genetically engineered probiotics, metabiotics), as well as the technique of transplantation of large intestine microbiota.


  1. Bengmark S. Nutrition and resistance to disease. In: Heidt PJ, Nieuwenhuis P, Rusch VD, van der Waaij D, editors. Old Herborn University Seminar Monographs 14: Intestinal translocation. Herborn Litterae: Herborn-Dill; 2001. p. 117–133.Google Scholar
  2. Bik EM, Ugalde JA, Cousins J, Goddard AD, Richman J, Apte ZS. Microbial biotransformations in the human distal gut. British J Pharmacology. 2018;175(24):4404–4414. doi: Scholar
  3. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA et al. Culturing of “unculturable” human microbiota reveals novel taxa and extensive sporulation. Nature. 2016;533:543–546. doi: Scholar
  4. Chervinets YuV, Chervinets VM, Shenderov BA. The modern view on the biotechnological potential of human symbiotic microbiota. Upper Volga medical journal. 2018;17(1):19–26 (in Russian).Google Scholar
  5. Dore J, Simren M, Buttle L, Guarner F. Hot topics in gut microbiota. United Europ Gastroenterol J. 2013;1(5):311–318. doi: Scholar
  6. Engevik MA, Versalovic J. Biochemical feature of beneficial microbes: foundation for therapeutic microbiology. Microbial Spectr. 2017;5(5). doi:
  7. Lebeer S, Bron PA, Marco ML, Van Pijkeren JP, O’Conell Motherway M et al. Identification of probiotic effect or molecules: present state and future perspectives. Curr Opin Biotechnol. 2018;49:217–223. doi: Scholar
  8. Lebeer S, Vanderleyden J, De Keersmaeker SCJ. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev. 2008;72(4):728–764. doi: Scholar
  9. Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Van Loo J, Sherman PM et al. Probiotic and probiotic influence beyond the intestinal tract. Nutr Rev. 2007;65(11):469–489. doi: Scholar
  10. Maguire M, Maguire G. Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics. Rev Neurosci. 2019;30(2):179–201. doi: Scholar
  11. Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics-Advances and challenges. Adv Drug Deliv Rev. 2016;105(Pt A):44–54. doi: Scholar
  12. Reid G, Younes JA, Mei Van der HC, Gloor GB et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27–38. doi: Scholar
  13. Roberfroid M, Gibson GR, Hoyles L, McCartney AL et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104 Suppl 2:1–63. doi: Scholar
  14. Shenderov BA. Functional nutrition and its role in the prevention of metabolic syndrome. Moscow: DeLi print; 2008 (in Russian).Google Scholar
  15. Shenderov BA. Probiotic (symbiotic) bacterial languages. Anaerobe. 2011;17(6):490–495. doi: Scholar
  16. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64. doi: Scholar
  17. Suvorov A. Gut microbiota, probiotics, and human health. Bioscience of Microbiota, Food and Health. 2013;32(3):81–91. doi: Scholar
  18. Venema K, do Carmo AP. Probiotic and Prebiotics: Current Research and Future Trends. Wageningen: Caiser Academic Press; 2015. doi:
  19. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterology Research and Practice. 2012;2012:872716. doi: Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Boris A. Shenderov
    • 1
  • Alexander V. Sinitsa
    • 2
  • Mikhail M. Zakharchenko
    • 2
  • Christine Lang
    • 3
  1. 1.Research Laboratory for Design & Implementation of Personalized Nutrition-Related Product & DietsK.G. Razumovsky University of Technology & ManagementMoscowRussia
  2. 2.Kraft Ltd.St. PetersburgRussia
  3. 3.MBCC GroupBerlinGermany

Personalised recommendations